佰泽医疗集团是一家主要从事投资及提供医疗相关服务的肿瘤医疗公司。该公司在肿瘤全周期医疗服务 领域提供服务，包括筛查、诊断、治疗及康复。该公司主要从事医院业务、医院管理服务、供应药品、 医疗设备及耗材及其他业务。该公司业务包括对患者开展肿瘤诊断、肿瘤治疗、肿瘤康复及临终关怀 等，以及对其他潜在健康人群开展的早癌筛查、肿瘤疫苗接种、健康管理服务。该公司主要在中国市场 开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-11 | 6083.28万 | -142.44万 | -2.29% | | 2025-12-10 | 6225.72万 | -21.42万 | -0.34% | | 2025-12-09 | 6247.14万 | 1.02万 | 0.02% | | 2025-12-08 | 6246.12万 | -51.36万 | -0.82% | | 2025-12-05 | 6297.4 ...

（原标题：融合聚力 精准康复！2025肿瘤康复论坛在天津举办） 共襄学术盛举，擘画肿瘤康复蓝图。12月5日，由天津市抗癌协会癌症康复工作委员会主办、佰泽医疗 集团协办的"融合聚力 精准康复——2025肿瘤康复论坛"在天津举办。本次论坛汇聚了肿瘤治疗、康 复、心理及中医等多领域权威专家，聚焦肿瘤康复前沿理念与实践路径，旨在推动肿瘤全周期管理模式 下康复医学的融合发展，提升患者生存质量。 《健康中国行动（2019—2030年）》指出，癌症严重影响人民健康，要重视康复治疗。《健康中国行动 —癌症防治行动实施方案（2023—2030年）》进一步明确：加强诊疗规范化管理，做好患者康复指导、 疼痛管理、长期护理和营养、心理支持。随着健康中国战略的深入推进和医学进步，我国肿瘤诊疗水平 显著提升，患者生存期持续延长。如何助力患者在延长生存时间的同时，全面提升其生活质量，促进其 身心的完整康复，已成为大家共同面临的时代课题。 基于此，佰泽医疗集团携旗下天津石氏医院协办此次大会。佰泽医疗集团（02609.HK）致力于打造中 国领先的肿瘤全周期医疗集团，经营6家自有民营营利性医院，管理及运营2家民营非营利性医院。作为 佰泽医疗集团 ...

Core Viewpoint - Baize Medical's successful debut on the Hong Kong Stock Exchange and the publication of the "Oncology Rehabilitation Expert Consensus (2025)" mark significant milestones for the company, emphasizing its focus on comprehensive cancer care services [1][2][4]. Group 1: Company Milestones - Baize Medical's stock price surged over 42% on its first trading day, reflecting strong investor confidence in its growth potential within the oncology sector [1]. - The "Oncology Rehabilitation Expert Consensus (2025)" introduces a new "full-cycle rehabilitation" framework, defining five key rehabilitation prescriptions and establishing the importance of multidisciplinary collaboration [2][4]. Group 2: Market Context - The oncology treatment sector is identified as a high-growth area due to increasing clinical demand and structural opportunities arising from the mismatch in China's healthcare resources [6]. - Current statistics indicate that China's five-year cancer survival rate is only 40.5%, significantly lower than the 67.1% in the U.S., highlighting the urgent need for improved cancer care resources [6]. Group 3: Policy and Industry Dynamics - Recent government policies aim to enhance private healthcare development, particularly in oncology, by guiding social capital into critical medical fields and reforming payment systems to create a fair environment for private hospitals [7]. - The number of private hospitals in China has grown from 20,977 in 2018 to 26,583 in 2023, with a projected increase to 44,063 by 2030, indicating a robust expansion in the private healthcare sector [7][8]. Group 4: Competitive Advantage - Baize Medical's strategy focuses on a full-cycle service model that integrates screening, diagnosis, treatment, and rehabilitation, creating a competitive edge in the oncology market [13][16]. - The company leads in early cancer screening capabilities among private oncology medical groups in China, with all its hospitals establishing specialized early cancer screening centers [15]. Group 5: Growth Strategy - Baize Medical plans to utilize approximately HKD 191 million (30.6% of net proceeds from its global offering) for acquiring quality hospital targets to enhance its network and specialized capabilities [21]. - The company is also investing around HKD 63.7 million (10.2% of proceeds) in upgrading its digital management systems to improve operational efficiency and patient management [22]. Group 6: Long-term Outlook - The combination of strategic acquisitions and digital technology integration is expected to drive Baize Medical's growth, positioning it well within the evolving oncology service landscape [18][22]. - The company's full-cycle service strategy aligns with national healthcare reforms aimed at enhancing cancer prevention and management, reinforcing its role as a key player in the industry [24][25].